Enriqueta Felip Font (Enriqueta Felip, E Felip)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 30

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Molecular oncology

Hospital Vall d'Hebron

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Hospital Vall d'Hebron

Spain

Head Thoracic Oncology Unit (After Competitive Exam) :: Medical Oncology

Hospital Vall d'Hebron

Spain

Head of Department (-PROVISIONAL-) :: Medical Oncology

Hospital Vall d'Hebron

Spain

Senior Clinical Attending Physician :: Medical Oncology

Hospital Vall d'Hebron

Spain

Clinical Attending Physician :: Medical Oncology

Hospital Vall d'Hebron

Spain

Resident in Medical Oncology :: Medical Oncology

Publications

Natasha B Leighl, Hiroaki Akamatsu, Sun Min Lim, Ying Cheng, Anna R Minchom, Melina E Marmarelis, Rachel E Sanborn, James Chih-Hsin Yang, Baogang Liu, Thomas John, Bartomeu Massuti, Alexander I Spira, Se-Hoon Lee, Jialei Wang, Juan Li, Caigang Liu, Silvia Novello, Masashi Kondo, Motohiro Tamiya, Ernesto Korbenfeld, Mor Moskovitz, Ji-Youn Han, Mariam Alexander, Rohit Joshi, Enriqueta Felip Font, Pei-Jye Voon, Pongwut Danchaivijitr, Ping-Chih Hsu, Felipe José Silva Melo Cruz, Thomas Wehler, Laurent Greillier, Encarnação Teixeira, Danny Nguyen, Joshua K Sabari, Angel Qin, Dariusz Mirosław Kowalski, Mehmet Ali Nahit Şendur, John Xie, Debopriya Ghosh, Ali A Alhadab, Nahor Haddish-Berhane, Pamela L Clemens, Patricia Lorenzini, Remy B Verheijen, Mohamed Gamil, Joshua M Bauml, Mahadi Baig, Antonio Passaro, null null
Subcutaneous versus Intravenous Amivantamab, both in Combination with Lazertinib, in Refractory EGFR -mutated NSCLC: Primary Results from the Phase 3 PALOMA-3 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Luis G Paz-Ares, Oscar Juan Vidal, Giannis S Mountzios, Enriqueta Felip Font, Niels Reinmuth, Filippo de Marinis, Nicolas Girard, Vipul M Patel, Takayuki Takahama, Scott P Owen, Douglas M Reznick, Firas B Badin, Irfan Cicin, Sabeen Mekan, Riddhi Patel, Eric Zhang, Divyadeep Karumanchi, Marina-Chiara Garassino
Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (24) (2024)
Afshin Dowlati, Horst-Dieter Hummel, Stephane Champiat, Maria Eugenia Olmedo, Michael J Boyer, Kai He, Neeltje Steeghs, Hiroki Izumi, Melissa Lynne Johnson, Tatsuya Yoshida, Hasna Bouchaab, Hossein Borghaei, Enriqueta Felip Font, Philipp J Jost, Shirish M Gadgeel, Xi Chen, Youfei Yu, Pablo Martinez, Amanda Parkes, Luis G Paz-Ares
Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Jessica J Lin, Joshua C Horan, Anupong Tangpeerachaikul, Aurélie Swalduz, Augusto Valdivia, Melissa Lynne Johnson, Benjamin Besse, D Ross Camidge, Toshio Fujino, Satoshi Yoda, Linh Nguyen-Phuong, Hayato Mizuta, Ludovic Bigot, Catline Nobre, Jii Bum Lee, Mi Ra Yu, Scot Mente, Yuting Sun, Nancy E Kohl, James R Porter, Matthew D Shair, Viola W Zhu, Enriqueta Felip Font, Byoung Chul Cho, Luc Friboulet, Aaron N Hata, Henry E Pelish, Alexander E Drilon
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations. Cancer discovery (2024)
Myung-Ju Ahn, Kentaro Tanaka, Luis G Paz-Ares, Robin Cornelissen, Nicolas Girard, Elvire Pons-Tostivint, David Vicente Baz, Shunichi Sugawara, Manuel Cobo, Maurice Pérol, Céline Mascaux, Elena V Poddubskaya, Satoru Kitazono, Hidetoshi Hayashi, Min Hee Hong, Enriqueta Felip Font, Richard Hall, Oscar Juan Vidal, Daniel Brungs, Shun Lu, Marina-Chiara Garassino, Michael J Chargualaf, Yong Zhang, Paul Howarth, Deise Uema, Aaron E Lisberg, Jacob M Sands, null null
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Benjamin J Solomon, Geoffrey Liu, Enriqueta Felip Font, Tony S K Mok, Ross Andrew Soo, Julien Mazieres, Alice T Shaw, Filippo de Marinis, Yasushi Goto, Yi-Long Wu, Dong Wan Kim, Jean-Francois Martini, Rossella Messina, Jolanda Paolini, Anna Polli, Despina Thomaidou, Francesca Toffalorio, Todd M Bauer
Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Luis G Paz-Ares, Oscar Juan Vidal, Giannis S Mountzios, Enriqueta Felip Font, Niels Reinmuth, Filippo de Marinis, Nicolas Girard, Vipul M Patel, Takayuki Takahama, Scott P Owen, Douglas M Reznick, Firas B Badin, Irfan Cicin, Sabeen Mekan, Riddhi Patel, Eric Zhang, Divyadeep Karumanchi, Marina-Chiara Garassino
Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Natasha B Leighl, Hiroaki Akamatsu, Sun Min Lim, Ying Cheng, Anna R Minchom, Melina E Marmarelis, Rachel E Sanborn, James Chih-Hsin Yang, Baogang Liu, Thomas John, Bartomeu Massuti, Alexander I Spira, Se-Hoon Lee, Jialei Wang, Juan Li, Caigang Liu, Silvia Novello, Masashi Kondo, Motohiro Tamiya, Ernesto Korbenfeld, Mor Moskovitz, Ji-Youn Han, Mariam Alexander, Rohit Joshi, Enriqueta Felip Font, Pei-Jye Voon, Pongwut Danchaivijitr, Ping-Chih Hsu, Felipe José Silva Melo Cruz, Thomas Wehler, Laurent Greillier, Encarnação Teixeira, Danny Nguyen, Joshua K Sabari, Angel Qin, Dariusz Mirosław Kowalski, Mehmet Ali Nahit Şendur, John Xie, Debopriya Ghosh, Ali A Alhadab, Nahor Haddish-Berhane, Pamela L Clemens, Patricia Lorenzini, Remy B Verheijen, Mohamed Gamil, Joshua M Bauml, Mahadi Baig, Antonio Passaro, null null
Subcutaneous versus Intravenous Amivantamab, both in Combination with Lazertinib, in Refractory EGFR -mutated NSCLC: Primary Results from the Phase 3 PALOMA-3 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Luis G Paz-Ares, Oscar Juan Vidal, Giannis S Mountzios, Enriqueta Felip Font, Niels Reinmuth, Filippo de Marinis, Nicolas Girard, Vipul M Patel, Takayuki Takahama, Scott P Owen, Douglas M Reznick, Firas B Badin, Irfan Cicin, Sabeen Mekan, Riddhi Patel, Eric Zhang, Divyadeep Karumanchi, Marina-Chiara Garassino
Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Luis G Paz-Ares, Oscar Juan Vidal, Giannis S Mountzios, Enriqueta Felip Font, Niels Reinmuth, Filippo de Marinis, Nicolas Girard, Vipul M Patel, Takayuki Takahama, Scott P Owen, Douglas M Reznick, Firas B Badin, Irfan Cicin, Sabeen Mekan, Riddhi Patel, Eric Zhang, Divyadeep Karumanchi, Marina-Chiara Garassino
Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Daniel Shao-Weng Tan, Enriqueta Felip Font, Gilberto de Castro Junior, Benjamin J Solomon, Alastair P Greystoke, Byoung Chul Cho, Manuel Cobo, Tae Min Kim, Sandip Ganguly, Enric Carcereny, Luis G Paz-Ares, Jaafar Bennouna, Marina-Chiara Garassino, Michael Schenker, Sang-We Kim, Jan C Brase, Denise Bury-Maynard, Vanessa Q Passos, Stéphanie Deudon, Bharani Dharan, Yuanbo Song, Rafael Caparica, Bruce E Johnson
Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Luis G Paz-Ares, Stephane Champiat, W Victoria Lai, Hiroki Izumi, Ramaswamy Govindan, Michael J Boyer, Horst-Dieter Hummel, Hossein Borghaei, Melissa Lynne Johnson, Neeltje Steeghs, Fiona Blackhall, Afshin Dowlati, Noemí Reguart, Tatsuya Yoshida, Kai He, Shirish M Gadgeel, Enriqueta Felip Font, Yiran Zhang, Amrita Pati, Mukul Minocha, Sujoy Mukherjee, Amanda Goldrick, Dirk Nagorsen, Nooshin Hashemi Sadraei, Taofeek Kunle Owonikoko
Tarlatamab, a First-In-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small Cell Lung Cancer: An Open-Label, Phase I Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Ernest Nadal, Delvys Rodriguez Abreu, Marta Simó, Bartomeu Massuti, Oscar Juan Vidal, Gerardo Huidobro, Rafael López-Castro, Javier De Castro Carpeño, Anna Estival Gonzalez, Joaquín Mosquera, Ivana G Sullivan, Enriqueta Felip Font, Ana Blasco, Maria Guirado, Eva Pereira, Noelia Vilariño, Valentín Navarro, Jordi Bruna
Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05). Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Gregory J Riely, Egbert F Smit, Myung-Ju Ahn, Enriqueta Felip Font, Suresh R Ramalingam, Anne S Tsao, Melissa Lynne Johnson, Francesco Gelsomino, Raymond Esper, Ernest Nadal, Michael D Offin, Mariano Provencio Pulla, Jeffrey Clarke, Maen Hussain, Gregory A Otterson, Ibiayi Dagogo-Jack, Jonathan Wade Goldman, Daniel Morgensztern, Ann Alcasid, Tiziana Usari, Paul S Wissel, Keith Wilner, Nuzhat Pathan, Svitlana Tonkovyd, Bruce E Johnson
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAF V600 -Mutant Metastatic Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Luis G Paz-Ares, Stephane Champiat, W Victoria Lai, Hiroki Izumi, Ramaswamy Govindan, Michael J Boyer, Horst-Dieter Hummel, Hossein Borghaei, Melissa Lynne Johnson, Neeltje Steeghs, Fiona Blackhall, Afshin Dowlati, Noemí Reguart, Tatsuya Yoshida, Kai He, Shirish M Gadgeel, Enriqueta Felip Font, Yiran Zhang, Amrita Pati, Mukul Minocha, Sujoy Mukherjee, Amanda Goldrick, Dirk Nagorsen, Nooshin Hashemi Sadraei, Taofeek Kunle Owonikoko
Tarlatamab, a first-in-class DLL3-targeted bispecific T cell engager, in recurrent small-cell lung cancer: an open-label, phase 1 study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Helena Alexandra Yu, Yasushi Goto, Hidetoshi Hayashi, Enriqueta Felip Font, James Chih-Hsin Yang, Martin Reck, Kiyotaka Yoh, Se-Hoon Lee, Luis G Paz-Ares, Benjamin Besse, Paolo Bironzo, Dong Wan Kim, Melissa Lynne Johnson, Yi-Long Wu, Thomas John, Steven Kao, Toshiyuki Kozuki, Erminia Massarelli, Jyoti D Patel, Egbert F Smit, Karen L Reckamp, Qian Dong, Pomy Shrestha, Pang-Dian Fan, Parul Patel, Andrea Sporchia, David W Sternberg, Dalila Sellami, Pasi A Janne
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Francisco Expósito, Miriam Redrado, Maeva Houry, Katherine Hastings, Magdalena Molero, Teresa Lozano, José Luis Solórzano, Julián Sanz, Vera Adradas, Ramon Amat, Esther Redin, Sergio Leon, Naroa Legarra, Javier Garcia, Angel Rodriguez, Karmele Valencia, Camila Robles-Oteíza, Giorgia Foggetti, Nerea Otegui, Enriqueta Felip Font, Juan Jose Lasarte, Luis G Paz-Ares, Jon Zugazagoitia, Katerina Politi, Luis M Montuenga, Alfonso Calvo
PTEN loss confers resistance to anti-PD-1 therapy in non-small cell lung cancer by increasing tumor infiltration of regulatory T cells. Cancer research (2023)
Misako Nagasaka, Yuichiro Ohe, Caicun Zhou, Chang-Min Choi, Nong Yang, Geoffrey Liu, Enriqueta Felip Font, Maurice Pérol, Benjamin Besse, Jorge J Nieva, Luis E Raez, Nathan A Pennell, Anastasios Dimou, Filippo de Marinis, Fortunato Ciardiello, Takashi Seto, Zheyi Hu, Max Pan, Weiqing Wang, Shuanglian Li, Sai-Hong Ignatius Ou
TRUST-II: a global phase II study of taletrectinib in ROS1 -positive non-small-cell lung cancer and other solid tumors. Future oncology (London, England) (2023)
Caterina Carbonell, Joan Frigola, Nuria Pardo, Ana Callejo, Patricia Iranzo, Augusto Valdivia, Ilaria Priano, Susana Cedrés, Alex Martinez-Marti, Alejandro Navarro, Laura Lenza, Mireia Soleda, Javier Gonzalo-Ruiz, Ana Vivancos, Miriam Sansó, Enric Carcereny, Teresa Morán, Ramon Amat, Enriqueta Felip Font
Dynamic changes in circulating tumor DNA assessed by shallow whole-genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC. Molecular oncology (2023)
Benjamin P Levy, Enriqueta Felip Font, Martin Reck, James Chih-Hsin Yang, Federico Cappuzzo, Yasuto Yoneshima, Caicun Zhou, Siddhartha Rawat, Jingdong Xie, Priyanka Basak, Lu Xu, Jacob M Sands
TROPION-Lung08: Phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC. Future oncology (London, England) (2023)
Marina-Chiara Garassino, Shirish M Gadgeel, Giovanna Speranza, Enriqueta Felip Font, Emilio Esteban, Manuel Dómine, Maximilian J Hochmair, Steven Francis Powell, Helge G Bischoff, Nir Peled, Francesco Grossi, Ross R Jennens, Martin Reck, Rina Hui, Edward B Garon, Takayasu Kurata, Jhanelle E Gray, Paul Schwarzenberger, Erin Jensen, M Catherine Pietanza, Delvys Rodriguez Abreu
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Caterina Carbonell, Joan Frigola, Nuria Pardo, Ana Callejo, Patricia Iranzo, Augusto Valdivia, Ilaria Priano, Susana Cedrés, Alex Martinez-Marti, Alejandro Navarro, Laura Lenza, Mireia Soleda, Javier Gonzalo-Ruiz, Ana Vivancos, Miriam Sansó, Enric Carcereny, Teresa Morán, Ramon Amat, Enriqueta Felip Font
Dynamic changes in circulating tumor DNA assessed by shallow whole-genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC. Molecular oncology (2023)
Karmele Valencia, Mirari Echepare, Andrea Pasquier, Cristina Bértolo, Cristina Sainz, Ibon Tamayo-Uria, Beñat Picabea, Graziella Bosco, Roman K Thomas, Jackeline Agorreta, José María López-Picazo, Joan Frigola, Ramon Amat, Alfonso Calvo, Enriqueta Felip Font, Ignacio Melero Bermejo, Luis M Montuenga
DSTYK inhibition increases the sensitivity of lung cancer cells to T cell-mediated cytotoxicity. The Journal of experimental medicine 219 (12) (2022)
Aleix Prat, Luis G Paz-Ares, Manel Juan, Enriqueta Felip Font, Elena Garralda, Blanca Gonzalez-Farre, Ana M Arance, Juan Martín-Liberal, Joaquín Gavilá, Ana López-González, Juan Miguel Cejalvo, Yann Izarzugaza, Kepa Amillano, Javier García Corbacho, Cristina Saura, Fabricio Racca, Cinta Hierro, Esther Sanfeliu, Xavier Gonzalez, Jordi Canes, Guillermo Villacampa, Fernando Salvador, Tomás Pascual, Ricard Mesía, Andres Cervantes, Josep Tabernero
SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA. Future oncology (London, England) (2022)
Ana Fernández Montes, Enriqueta Felip Font
SEOM clinical guidelines (2021). Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 24 (4) (2022)
Vladimir Lazar, Nicolas Girard, Eric Raymond, Jean-Francois Martini, Susan Galbraith, Jacques Raynaud, Catherine Bresson, Benjamin Solomon, Shai Magidi, Hovav Nechushtan, Amir Onn, Raanan Berger, Haiquan Chen, Amal Al-Omari, Sadakatsu Ikeda, Ulrik N Lassen, Marina Sekacheva, Enriqueta Felip Font, Josep Tabernero, Gerald Batist, Alan Spatz, Conjeevaram S Pramesh, Philippe Girard, Jean Yves Blay, Thierry Philip, Ioana Berindan Neagoe, Angel Porgador, Eitan Rubin, Razelle Kurzrock, Richard L Schilsky
Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non-Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies. JCO precision oncology 6 (2022)
Hossein Borghaei, Scott N Gettinger, Everett E Vokes, Laura Q M Chow, Marco Angelo Burgio, Javier De Castro Carpeño, Adam Pluzanski, Arrieta Oscar, Osvaldo Arén Frontera, Rita Chiari, Charles Butts, Joanna Wójcik-Tomaszewska, Bruno Coudert, Marina Chiara Garassino, Neal Ready, Enriqueta Felip Font, Miriam Alonso García, David Michael Waterhouse, Manuel Dómine, Fabrice Barlesi, Scott Antonia, Markus Wohlleber, David E Gerber, Grzegorz Czyzewicz, David R Spigel, Lucio Crino, Wilfried Enst Erich Eberhardt, Ang Li, Sathiya Marimuthu, Julie Brahmer
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (7) (2021)
Marta Ligero, Alonso Garcia-Ruiz, Cristina Viaplana, Guillermo Villacampa, Maria Vittoria Raciti, Jaid Landa, Ignacio Matos, Juan Martin-Liberal, Maria Ochoa de Olza, Cinta Hierro, Joaquin Mateo, Macarena Gonzalez, Rafael Morales-Barrera, Cristina Suarez, Jordi Rodon, Elena Elez, Irene Braña, Eva Muñoz Couselo, Ana Oaknin, Roberta Fasani, Paolo Nuciforo, Debora Gil, Carlota Rubio-Perez, Joan Seoane, Enriqueta Felip Font, Manuel Escobar, Josep Tabernero, Joan Carles, Rodrigo Dienstmann, Elena Garralda, Raquel Perez-Lopez
A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. Radiology 299 (1) (2021)
Gregory J Riely, Myung-Ju Ahn, Enriqueta Felip Font, Suresh R Ramalingam, Egbert F Smit, Anne S Tsao, Ann Alcasid, Tiziana Usari, Paul S Wissel, Keith D Wilner, Bruce E Johnson
Encorafenib plus binimetinib in patients with BRAF V600 -mutant non-small cell lung cancer: phase II PHAROS study design. Future oncology (London, England) 18 (7) (2021)
Dolores Isla, Javier De Castro Carpeño, R García-Campelo, Pilar Lianes, Enriqueta Felip Font, Pilar Garrido Lopez, Luis G Paz-Ares, J M Trigo
Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 22 (5) (2019)

Enriqueta Felip Font.css-eqlu8i{font-size:small;padding-left:4px;} (Enriqueta Felip, E Felip)

Publication Activity (10 Years)

Top Topics

Top Venues

Enriqueta Felip Font (Enriqueta Felip, E Felip)